NDAORALTABLET
Approved
May 1960
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
EQUAGESIC (aspirin; meprobamate) by PharmaIN is clinical pharmacology meprobamate is a carbamate derivative which has been shown (in animal and/or human studies) to have effects at multiple sites in the central nervous system, including the thalamus and limbic system. Approved for anxiety. First approved in 1960.
Drug data last refreshed 2h ago · AI intelligence enriched 5d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EQUAGESIC is an oral combination tablet containing aspirin and meprobamate, approved in 1960 for anxiety treatment. Meprobamate acts on the thalamus and limbic system to reduce anxiety, while aspirin provides nonnarcotic analgesia with antipyretic and anti-inflammatory properties. This fixed-dose combination targets patients requiring both anxiolytic and analgesic relief.
LOE Approaching
As a product in LOE-approaching stage with minimal current spending data, career opportunities are limited to legacy maintenance roles rather than growth-focused positions.
Mechanism of Action
CLINICAL PHARMACOLOGY Meprobamate is a carbamate derivative which has been shown (in animal and/or human studies) to have effects at multiple sites in the central nervous system, including the thalamus and limbic system. Aspirin is a nonnarcotic analgesic with antipyretic and anti-inflammatory…
Indications (1)
Career Relevance
EQUAGESIC offers minimal career advancement opportunity due to its LOE-approaching status, negligible current market spending, and lack of clinical development pipeline. Professionals assigned to this product should expect limited headcount, constrained budgets, and focus on legacy account maintenance rather than growth initiatives.
Worked on EQUAGESIC at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.